Suppr超能文献

用于定量循环肿瘤DNA中基因突变的严格碱基特异性且无需优化的多重介导探针数字PCR

Stringent Base Specific and Optimization-Free Multiplex Mediator Probe ddPCR for the Quantification of Point Mutations in Circulating Tumor DNA.

作者信息

Schlenker Franziska, Kipf Elena, Deuter Max, Höffkes Inga, Lehnert Michael, Zengerle Roland, von Stetten Felix, Scherer Florian, Wehrle Julius, von Bubnoff Nikolas, Juelg Peter, Hutzenlaub Tobias, Borst Nadine

机构信息

Hahn-Schickard, Georges-Koehler-Allee 103, 79110 Freiburg, Germany.

Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.

出版信息

Cancers (Basel). 2021 Nov 16;13(22):5742. doi: 10.3390/cancers13225742.

Abstract

There is an increasing demand for optimization-free multiplex assays to rapidly establish comprehensive target panels for cancer monitoring by liquid biopsy. We present the mediator probe (MP) PCR for the quantification of the seven most frequent point mutations and corresponding wild types ( and ) in colorectal carcinoma. Standardized parameters for the digital assay were derived using design of experiments. Without further optimization, the limit of detection (LoD) was determined through spiking experiments with synthetic mutant DNA in human genomic DNA. The limit of blank (LoB) was measured in cfDNA plasma eluates from healthy volunteers. The 2-plex and 4-plex MP ddPCR assays showed a LoB of 0 copies/mL except for 4-plex G13D (9.82 copies/mL) and 4-plex V600E (16.29 copies/mL) and allele frequencies of 0.004% ≤ LoD ≤ 0.38% with R ≥ 0.98. The quantification of point mutations in patient plasma eluates (18 patients) during follow-up using the 4-plex MP ddPCR showed a comparable performance to the reference assays. The presented multiplex assays need no laborious optimization, as they use the same concentrations and cycling conditions for all targets. This facilitates assay certification, allows a fast and flexible design process, and is thus easily adaptable for individual patient monitoring.

摘要

对于无需优化的多重检测方法的需求日益增长,以便通过液体活检快速建立用于癌症监测的综合靶标panel。我们提出了介体探针(MP)PCR,用于定量结直肠癌中七种最常见的点突变及其相应的野生型(和)。使用实验设计得出数字检测的标准化参数。无需进一步优化,通过在人基因组DNA中加入合成突变DNA进行加标实验来确定检测限(LoD)。在健康志愿者的cfDNA血浆洗脱液中测量空白限(LoB)。除了4重检测G13D(9.82拷贝/mL)和4重检测V600E(16.29拷贝/mL)外,2重和4重MP ddPCR检测的LoB为0拷贝/mL,等位基因频率为0.004%≤LoD≤0.38%,R≥0.98。使用4重MP ddPCR对18例患者随访期间血浆洗脱液中的点突变进行定量,结果显示其性能与参考检测相当。所提出的多重检测无需繁琐的优化,因为它们对所有靶标使用相同的浓度和循环条件。这便于检测认证,允许快速灵活的设计过程,因此易于适用于个体患者监测。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fba9/8616434/b484339a1181/cancers-13-05742-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验